附件99.1

Valneva宣佈年度股東大會取得成功並任命兩名新的監事會成員

聖赫布賴恩(法國)，2022年6月24日-特種疫苗公司Valneva SE(納斯達克：VALN；泛歐交易所股票代碼：VLA)今天宣佈，昨天在巴黎舉行的股東年度大會(AGM)上，董事會建議的所有決議都得到了股東的批准。

通過的決議包括批准2021年財務報表、授權管理委員會 增加Valneva的股本和/或發行金融工具，以及任命兩名新的監事會成員，任期三年。

Bpifrance Participations被任命為Valneva監事會成員，將由Maílys Ferrère代表。 費雷爾女士是法國國有投資銀行Bpifrance大型風險投資公司的董事總裁。 在Bpifrance擔任董事期間，她是泛歐交易所上市公司的多個董事會成員。在2013年加入Bpifrance Large Venture之前，費雷爾女士是Fond Stratégique d‘InvestsDepartment的董事投資人。在此之前，Ferrère女士的職業是銀行業，專注於各種金融機構的股權資本市場。她畢業於巴黎政治學院。

美國人詹姆斯·愛德華·康諾利也被任命為瓦爾內瓦監事會成員。康諾利先生是一位經驗豐富的企業高管，在生命科學行業擁有30多年的經驗。自2013年以來，康諾利先生一直在多家疫苗、生物製藥和投資機構的董事會任職。2010至2013年，康諾利先生擔任AERAS(現為IAVI)總裁兼首席執行官。在此之前，他在惠氏(現為輝瑞)有長達24年的成功職業生涯，在那裏他擔任了一系列高級職位，最後兩個職位是惠氏疫苗執行副總裁兼總經理和惠氏加拿大公司總裁。在領導惠氏疫苗期間，康諾利發揮了領導作用，將該公司的疫苗業務 打造成全球四大製造商之一，並創造了第一個真正的重磅炸彈疫苗Prevnar，銷售額超過30億美元。

此外，監事會成員弗雷德裏克·格里莫、詹姆斯·蘇拉特和安妮·瑪麗·格拉芬的任期延長至2025年6月。在另一次會議上，弗雷德裏克·格里莫再次當選為Valneva監事會主席。

Valneva還在年度股東大會上證實，萊姆病候選疫苗VLA15 的第三階段研究計劃於2022年第三季度啟動，預計將在2022年下半年向食品和藥物管理局(FDA)提交其基孔肯雅候選疫苗VLA1553的生物製品許可證申請(BLA)。

年度股東大會的投票結果將在未來幾天在Valneva公司網站的“投資者和媒體”部分公佈。

關於Valneva SE
Valneva是一家專業疫苗公司，專注於針對重大醫療需求未得到滿足的傳染病的預防性疫苗的開發和商業化。該公司採取高度專業化和針對性的方法進行疫苗開發，然後應用其對疫苗科學的深刻理解來開發針對這些疾病的預防性疫苗 。Valneva利用其專業知識和能力成功地將兩種疫苗商業化，並迅速將各種候選疫苗 推向臨牀並通過臨牀推廣，包括萊姆病、基孔肯雅病毒和新冠肺炎的候選疫苗。

Valneva前瞻性陳述
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates and estimates for future performance. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.